15/12/2022 Cognition Therapeutics expands its SHINE Phase II trial for mild to moderate AD in Europe Science watch
06/12/2022 Otsuka and Lundbeck presents positive data from phase III studies with brexpiprazole for agitation in AD Science watch
06/12/2022 New study investigates the association between antidementia medication use and mortality in people with dementia with Lewy bodies Science watch
02/12/2022 Treatment with anti-depressant drug mirtazapine does not reduce agitation in people with Alzheimer’s disease, according to recent SYMBAD trial results Science watch
02/12/2022 Interim analysis of Phase 2 biomarker study of ALZ-801 presented by Alzheon at CTAD Science watch
01/12/2022 Scottish FA completes research into heading the ball in football training and introduces new guidance for the adult game Science watch
01/12/2022 Early start of anti-dementia medication is linked to lower health and social care costs, according to a Finnish health economics study Science watch
01/12/2022 AC Immune announces further development of its ACI-35.030 vaccine candidate for Alzheimer’s disease Science watch
30/11/2022 Axsome Therapeutics’s experimental drug AXS-05 meets its primary endpoint in Phase III of AD agitation Science watch
